Jinwan Wang

5.6k citations
90 papers · 2.7k · 2 hit papers · h-index 21

Impact in

  • Oncology top 2%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
    • Peptidase Inhibition and Analysis
    • Gastrointestinal Tumor Research and Treatment

Papers in

    • Gastric Cancer Management and Outcomes 24
    • Renal cell carcinoma treatment 18
    • Lung Cancer Treatments and Mutations 9
    • Colorectal Cancer Treatments and Studies 22
    • Lung Cancer Research Studies 16
    • HER2/EGFR in Cancer Research 8
    • Peptidase Inhibition and Analysis 7

Jinwan Wang

86 papers receiving 2.7k citations

Hit Papers

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors 2016 · 332 citations
3320+4+8Years since publication100200300400

Peers

Jinwan Wang
Comparison fields: 5 of 125
  • Oncology 1.5k
  • Gastroenterology 296
  • Pulmonary and Respiratory Medicine 1.4k
  • Surgery 552
  • Cancer Research 181
Replace Shigenori Kadowaki with:
Shigenori Kadowaki Japan
Fumio Nagashima Japan
Weihan Zhang China
Atsushi Arakawa Japan
Dorothea Wagner Germany
Masayoshi Yasui Japan
Sambasiva Rao United States
Wooil Kwon South Korea
Kazuya Endo Japan
Hiroyuki Okuda Japan
Jinwan Wang relative to Shigenori Kadowaki Japan Shigenori Kadowaki's profile →
Citations per field
00.5×2.6×
Shigenori Kadowaki · 1×
Citations per year

Countries citing papers authored by Jinwan Wang

Since Specialization
Citations

This map shows the geographic impact of Jinwan Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinwan Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinwan Wang more than expected).

Fields of papers citing papers by Jinwan Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinwan Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinwan Wang. The network helps show where Jinwan Wang may publish in the future.

Co-authors

The 25 scholars most cited alongside Jinwan Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jinwan Wang Line = papers co-authored together Jinwan Wang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 90 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
Hit paper breakdown →
2014474
2
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Hit paper breakdown →
2016332
3 2018245
4 2016193
5 2014184
6 201891
7 201388
8 201980
9 201577
10 201672
11 200871
12 201250
13 201647
14 201445
15 201743
16 201538
17 201336
18
[Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer].
200635
19 202224
20 202022

About Jinwan Wang

Jinwan Wang is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Epidemiology and Molecular Biology, having authored 90 papers that have together received 2.7k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (24 papers), Colorectal Cancer Treatments and Studies (22 papers), Renal cell carcinoma treatment (18 papers), Lung Cancer Research Studies (16 papers), Neuroendocrine Tumor Research Advances (12 papers), Lung Cancer Treatments and Mutations (9 papers), HER2/EGFR in Cancer Research (8 papers) and Peptidase Inhibition and Analysis (7 papers). The work is most often cited by research in Oncology (1.5k citations), Gastroenterology (296 citations), Pulmonary and Respiratory Medicine (1.4k citations), Surgery (552 citations) and Cancer Research (181 citations). Jinwan Wang has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Wentao Mao, Yihebali Chi, Yongkun Sun, Feng Du, Ling He, Hao Yu, Rui‐Hua Xu, Jianming Xu, Chunxia Du and Shuting Li. Their work appears in journals such as Journal of Clinical Oncology, BMC Cancer, Gastric Cancer, The Oncologist and Journal of Surgical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact